<DOC>
	<DOCNO>NCT00617305</DOCNO>
	<brief_summary>To evaluate change baseline pulmonary vascular resistance ( PVR ) , hemodynamic parameter , follow addition ambrisentan background phosphodiesterase type-5 inhibitor ( PDE-5i ) therapy subject pulmonary arterial hypertension ( PAH ) demonstrate sub-optimal response PDE-5i monotherapy . The study originally design 2-arm , double-blind , randomized study patient receive ambrisentan placebo 24 week , receive ambrisentan blind dose 24 week . With Protocol Amendment 2 ( 12 June , 2009 ) , study switch single-arm , open-label treatment , patient remain placebo arm switch open-label ambrisentan treatment . Patients enrol Amendment 2 receive open-label ambrisentan .</brief_summary>
	<brief_title>Study Add-on Ambrisentan Therapy Background Phosphodiesterase Type-5 Inhibitor ( PDE5i ) Therapy Pulmonary Arterial Hypertension ( ATHENA-1 )</brief_title>
	<detailed_description>The primary objective study evaluate change baseline pulmonary vascular resistance ( PVR ) , hemodynamic parameter , follow addition ambrisentan background phosphodiesterase type-5 inhibitor ( PDE-5i ) therapy subject pulmonary arterial hypertension ( PAH ) demonstrate sub-optimal response PDE-5i monotherapy . The secondary objective study evaluate change baseline clinical measure PAH follow addition ambrisentan background PDE-5i therapy subject PAH demonstrate sub-optimal response PDE-5i monotherapy . The safety tolerability ambrisentan/PDE-5i combination therapy evaluate throughout study . In addition , long-term efficacy examine .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Selected Inclusion Criteria Must 16 75 year age ; Must weigh least 40 kg ; Have current diagnosis idiopathic PAH , familial PAH , PAH primarily due connective tissue disease , congenital heart defect , drug toxin use , human immunodeficiency virus ( HIV ) ; Have WHO functional class III symptom ; Be receive sildenafil tadalafil monotherapy treatment PAH least past 12 week stable dose least 8 consecutive week ; Meet follow hemodynamic criterion mean right heart catheterization : mPAP least 25 mmHg ; PVR least 400 dyne*sec/cm5 ; pulmonary capillary wedge pressure ( PCWP ) leave ventricular end diastolic pressure ( LVEDP ) 15 mmHg ; Meet follow pulmonary function test criterion 12 week screen visit : total lung capacity least 60 % predict normal forced expiratory volume 1 second least 65 % predict normal ; Able walk least 150 meter screen 6minute walk test ( 6MWT ) ; If receive calcium channel blockers 5hydroxy3methylglutarylcoenzyme A reductase inhibitor ( i.e. , statin ) must stable therapy least 4 week ; If diagnose HIV , must stable disease status . Selected Have current pulmonary hypertension diagnosis idiopathic PAH , familial PAH , PAH primarily due connective tissue disease , congenital heart defect , drug toxin use , HIV ; Have leave ventricular ejection fraction ( LVEF ) â‰¤40 % clinically significant ischemic , valvular , constrictive heart disease ; Have receive chronic prostanoid endothelin receptor antagonist ( ERA ) therapy ( eg , bosentan , sitaxsentan ) within past 12 week ; Have discontinue ERA treatment adverse reaction associate liver function test abnormality ; Have receive IV inotropes within 2 week ; Have serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value great 2.0x upper limit normal .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>ambrisentan</keyword>
	<keyword>PAH</keyword>
	<keyword>combination therapy</keyword>
	<keyword>phosphodiesterase type-5 inhibitor ( PDE-5i )</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>endothelin receptor antagonist</keyword>
	<keyword>ERA</keyword>
</DOC>